Yahoo Finance

Ascidian Therapeutics Appoints Dr. Murray A. Abramson as Chief Development Officer and Establishes Ophthalmology Clinical Advisory Board to Advance ACDN-01 for Treatment of ...

BOSTON, June 24, 2025 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the appointment of Murray A. Abramson, MD, MPH, ...
Yahoo Finance

Ascidian Therapeutics and Forge Biologics Announce Manufacturing Partnership to Advance RNA Editing Therapy for Stargardt Disease

BOSTON & COLUMBUS, Ohio, January 07, 2026--(BUSINESS WIRE)--Ascidian Therapeutics ("Ascidian"), a biotechnology company seeking to treat human diseases by rewriting RNA, and Forge Biologics ("Forge"), ...
BioWorld

ACDN-01 results in robust, durable and well-tolerated ABCA4 exon editing in preclinical models

Ascidian Therapeutics Inc. recently provided preclinical data for ACDN-01, an AAV-encoded RNA exon editor targeting ABCA4, being developed for the treatment of ABCA4-related retinopathies, including ...
PharmTech

Roche and Ascidian Therapeutics Collaborate on Treatments for Neurological Diseases

The research collaboration and licensing agreement will focus on the discovery and development of RNA exon editing therapeutics. Ascidian Therapeutics, a biotechnology company developing treatments by ...
NBC4 Columbus

THE POWER OF AND: CELEBRATING WOMEN'S HISTORY MONTH WITH ACDN'S SMART & SEXY DAY

WASHINGTON, DC, UNITED STATES, February 28, 2025 /EINPresswire.com/ -- The Alliance of Career Development Nonprofits (ACDN) is proud to present Smart & Sexy Day 2025 ...
Business Wire

Ascidian Therapeutics and Forge Biologics Announce Manufacturing Partnership to Advance RNA Editing Therapy for Stargardt Disease

Forge’s FUEL™ platform and cGMP manufacturing services support the production of AAV for Ascidian’s ACDN-01, the most advanced genetic therapy targeting the underlying cause of Stargardt disease ...